Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Aug 4;8(9):bvae142. doi: 10.1210/jendso/bvae142

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. See the journal About page for additional terms.

PMC Copyright notice

Figure 2. — Succinate to fumarate ratio determined in heparin plasma by LC-MS/MS. Plasma was collected from patients with PPGL (cohort A) either preoperatively (Pre-OP, A) or postoperatively (Post-OP, B). C) Paired analysis between pre-OP and post-OP samples; P value represents Wilcoxon signed-rank test (1-tailed for SDHx, 2-tailed for non-SDHx). D) Decrease in the succinate to fumarate ratio according to genes in % (Kruskal-Wallis test). E) Correlation between pre-OP succinate to fumarate ratios and tumor volume (natural logarithm of value in cm³ displayed). F. Succinate to fumarate ratio according to the affected gene comparing patients with germline SDHA (black dots) and SDHB (gray dots) PVs to patients with SDHC (black dots) and SDHD (gray dots) PVs (Kruskal-Wallis test).